# P-MUC1C-ALLO1 in advanced solid tumors

Source: https://onco.cc/trials/nct05239143/  
OnCo record `nct05239143` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study tests donor-derived immune cells engineered to recognize a tumor-associated protein. It evaluates dose and safety across selected advanced solid tumors.

## Summary

This early study tests donor-derived immune cells engineered to recognize a tumor-associated protein. It evaluates dose and safety across selected advanced solid tumors.

Interventional study registered as NCT05239143, sponsored by Poseida Therapeutics, Inc.. Registry phase: 1. Registry enrollment is 180 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT05239143
- Phase: 1
- Setting: Advanced or metastatic epithelial solid tumors
- Sponsor: Poseida Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT05239143: https://clinicaltrials.gov/study/NCT05239143
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT05239143

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct05239143.json